Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/50022
Title: Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
Authors: Kitsada Wudhikarn
Udomsak Bunworasate
Jakrawadee Julamanee
Arnuparp Lekhakula
Supachai Ekwattanakit
Archrob Khuhapinant
Pimjai Niparuck
Suporn Chuncharunee
Tontanai Numbenjapon
Kannadit Prayongratana
Nonglak Kanitsap
Somchai Wongkhantee
Nisa Makruasri
Peerapon Wong
Lalita Norasetthada
Weerasak Nawarawong
Chittima Sirijerachai
Kanchana Chansung
Tawatchai Suwanban
Pannee Praditsuktavorn
Tanin Intragumtornchai
Chulalongkorn University
Naresuan University
Khon Kaen University
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Thammasat University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Phramongkutklao College of Medicine
Prince of Songkla University
Rajavithi Hospital
Chiang Mai University
Srinakharinwirot University
Khonkaen Regional Hospital
Chulabhorn Hospital
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Dec-2019
Citation: Hematological Oncology. Vol.37, No.5 (2019), 578-585
Abstract: ©2019 John Wiley & Sons, Ltd. Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2-year EFS and 2-year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2-y OS 92% vs 18.8%; HR, 0.1; P <.001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6-22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/50022
metadata.dc.identifier.url: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075039642&origin=inward
ISSN: 10991069
02780232
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.